Urokinase-type plasminogen activator, plasminogen activator inhibitor type1 and cathepsin D: Analysis of their prognostic significance in squamous cell carcinoma of the head and neck

Background: The aim of the study was to evaluate the prognostic significanc e of tumour and serum concentrations of urokinase-type plasminogen activato r (uPA), its type 1 inhibitor (PAI-1) and cathepsin D (Cath D) in patients with squamous cell carcinoma of the head and neck (SCCHN). Patients and Met hods: Determinations of uPA and PAI-1 were made using enzyme-linked immunos orbent assays in tumour and serum samples of 47 and 32/47 patients, respect ively. For the determination of tumour (94 patients) and serum (34/94 patie nts) Cath D concentrations, an immunoradiometric assay was used. Results: I n an univariate survival analysis, the risk of disease recurrence and SCCHN -related death was significantly higher in the patients with high uPA (P=0. 046, P=0.010) tumours, compared to those with low uPA armours. In addition, the high serum levels of uPA correlated positively with the rare of relaps e (P=0.007), but not with the mortality rate (P=0.200). There was no statis tically significant difference between low and high PAI-1 groups, regarding either tumour or serum concentration of the inhibitor, and between low and high Cath D tumours. Low Cath D serum levels appeared to be related to lon ger disease-free interval (P=0.055) but not to disease-specific survival (P =0.120). Conclusions: The tumour levels of uPA, as well as serum levels of uPA and Cath D could potentially predict the survival probability of patien ts with SCCHN. However, the strength of this association remains to be inve stigated on a larger and more homogenous group of patients.